The prominence of tobacco and its relationship to dying prematurely from cancer cannot be understated. Cigarettes contain more than 60 human carcinogenic substances that are considered responsible for one-third of all cancer deaths. In addition to lung cancer, tobacco is also associated with nasopharyngeal, esophageal, hepatic, gastric, pancreatic, renal, bladder, ureter, ovarian colorectal, and cervical solid tumors as well as acute myeloid leukemia. Hence tobacco remains the most significant global potentially preventable cause of cancer.
Overall, tobacco control has been associated with an avoidance of 8 million premature deaths and an estimated extended mean life span of approximately 2 decades.1 A recent article by Bialous and Sarna2 addressed contemporary findings related to lung cancer and tobacco. Of note was their depiction of evidence regarding the positive impact of quitting tobacco use along the lung cancer continuum.
The health benefits of tobacco cessation are numerous in both the short- and long-term paradigms. These include documented results in immediate outcome (i.e., toxicity prominence) and overall survival. Interventions to minimize tobacco dependence are required to offset the negative sequelae of the initiation, promotion, and management of cancer. Of note also is the impact of managing the corollary of depressive symptoms commonly associated with smoking behaviors.3
Holford TR, Meza R, Warner KE, et al. Tobacco control and the reduction in smoking-related premature deaths in the United States, 1964–2012. JAMA. 2014 Jan 8;311(2):164-71.
Bialous SA, Sarna L. Lung Cancer and Tobacco: What Is New? Nurs Clin North Am. 2017 Mar;52(1):53-63.
Berg CJ, Thomas AN, Mertens AC, et al. Correlates of continued smoking versus cessation among survivors of smoking-related cancers. Psychooncology. 2013 Apr;22(4):799-806.
FDA Approves Onivyde for Advanced Pancreatic Cancer Marijke Vroomen Durning, RN, 10/27/2015 3 On October 22, 2015, the US Food and Drug Administration (FDA) approved Onivyde (irinotecan liposome injection, Merrimack Pharmaceuticals, Inc.), in combination with fluorouracil ...